Lundh Andreas, Knijnenburg Sebastiaan L, Jørgensen Anders W, van Dalen Elvira C, Kremer Leontien C M
Department of Pediatric Oncology, Emma Children's Hospital/Academic Medical Center, University of Amsterdam, 1100 DD Amsterdam, The Netherlands.
Cancer Treat Rev. 2009 Dec;35(8):645-52. doi: 10.1016/j.ctrv.2009.08.010.
To ensure evidence-based decision making in pediatric oncology systematic reviews are necessary. The objective of our study was to evaluate the methodological quality of all currently existing systematic reviews in pediatric oncology.
We identified eligible systematic reviews through a systematic search of the literature. Data on clinical and methodological characteristics of the included systematic reviews were extracted. The methodological quality of the included systematic reviews was assessed using the overview quality assessment questionnaire, a validated 10-item quality assessment tool. We compared the methodological quality of systematic reviews published in regular journals with that of Cochrane systematic reviews.
We included 117 systematic reviews, 99 systematic reviews published in regular journals and 18 Cochrane systematic reviews. The average methodological quality of systematic reviews was low for all ten items, but the quality of Cochrane systematic reviews was significantly higher than systematic reviews published in regular journals. On a 1-7 scale, the median overall quality score for all systematic reviews was 2 (range 1-7), with a score of 1 (range 1-7) for systematic reviews in regular journals compared to 6 (range 3-7) in Cochrane systematic reviews (p<0.001).
Most systematic reviews in the field of pediatric oncology seem to have serious methodological flaws leading to a high risk of bias. While Cochrane systematic reviews were of higher methodological quality than systematic reviews in regular journals, some of them also had methodological problems. Therefore, the methodology of each individual systematic review should be scrutinized before accepting its results.
为确保儿科肿瘤学领域基于证据的决策制定,系统评价是必要的。我们研究的目的是评估目前所有儿科肿瘤学系统评价的方法学质量。
我们通过系统检索文献来识别合格的系统评价。提取纳入系统评价的临床和方法学特征数据。使用概述质量评估问卷(一种经过验证的10项质量评估工具)评估纳入系统评价的方法学质量。我们比较了发表在普通期刊上的系统评价与Cochrane系统评价的方法学质量。
我们纳入了117项系统评价,其中99项发表在普通期刊上,18项为Cochrane系统评价。所有十项指标的系统评价平均方法学质量较低,但Cochrane系统评价的质量显著高于发表在普通期刊上的系统评价。在1至7分的量表上,所有系统评价的总体质量得分中位数为2(范围1至7),普通期刊上的系统评价得分为1(范围1至7),而Cochrane系统评价为6(范围3至7)(p<0.001)。
儿科肿瘤学领域的大多数系统评价似乎存在严重的方法学缺陷,导致偏倚风险较高。虽然Cochrane系统评价的方法学质量高于普通期刊上的系统评价,但其中一些也存在方法学问题。因此,在接受每个系统评价的结果之前,应仔细审查其方法学。